Dear Editor, In a previous letter "Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome" [1] , the authors state that in using the established flow cytometric scoring system (FCM) from our manuscript by Chu et al. [2] , a case of vitamin B 12 deficiency was suspicious for myelodysplastic syndrome by showing an abnormal CD13/CD11b pattern.
We respectfully disagree with the following points:
1. The FCM, validated in multiple studies, [3, 4] did not use the reagent combination described: the exact antibody combinations and relationships as published are the only studies validated and, therefore, the only correct context of use for FCM. 2. If the abnormal CD13/CD11b were an isolated (single) abnormality, the FCM would be 1, with a sensitivity of 84 % (stated in the Chu's manuscript), and in the original paper by Wells et al., a score of 1 was described as below the cutoff for myelodysplastic syndrome (MDS) when compared to non-MDS controls.
(a) The letter erroneously states that an FCM score of 1 was described in our validated studies as an "intermediate risk." (b) The paper by Chu et al. stated that single abnormalities are occasionally observed in the CD13/ CD16 relationship in vitamin B 12 deficiency anemia.
In conclusion, based on utilization of the FCM as validated, we do not concur that there is evidence by flow cytometry from the data provided to make a diagnosis or suspicion of MDS in this case. The karyotyping results are concerning for an underlying dysplasia that is now masked by recovering hematopoiesis and additional follow-up is warranted.
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